Reassessing Biomarkers: Guiding Second-Line Therapy in Upper GI Cancer

Opinion
Video

Experts discuss how biomarker testing results should be reassessed or expanded upon disease progression and how they guide the selection of second-line therapies or clinical trial enrollment.

Recent Videos
5 experts in this video
5 experts in this video
Related Content